By Dean Seal


Shares of Cerus gained after positive results were disclosed in a Phase 3 trial of its INTERCEPT Red Blood Cells being transfused to complex cardiac surgery patients.

The stock rose 10% to $2.05 in the first few hours of the trading day. Shares are still 5% lower than where they started the year.

The biotechnology company said Tuesday that the trial met its primary efficacy endpoint and showed non-inferiority for the INTERCEPT blood cells compared with conventional red blood cells as measured by incidence of acute kidney injury.

Cerus anticipated initiating a premarket approval application with the U.S. Food and Drug Administration in the second half of next year.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

03-19-24 1212ET